This recession has been particularly hard on Connecticut’s small bioscience companies.
The state remains in the forefront of some cutting edge sectors like stem cell research, and it recently got a pat on the back for the way it prepares its middle and high school students in bioscience disciplines.
But actual dollars to fund costly biotech research have all but dried up in the last year or so.
Some companies, like Curagen, have agreed to be sold in order to keep operating. Others continue to pursue the sale of some or all of their assets.
WNPR’s Harriet Jones spoke with Paul Pescatello, who heads up CURE, Connecticut’s bioscience cluster.